Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | AHCY | P23526 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902586 | 0.88 | HPRT1 (0.43) | FGFR1SLC22A6HPRT1ADKAHCY | |
| SCHEMBL6905254 | 0.87 | DNPH1 (0.42) | FGFR1SLC22A6HPRT1CYP3A4DNPH1 | |
| SCHEMBL6328404 | 0.85 | ADK (0.32) | FGFR1SLC22A6HPRT1ADK | |
| SCHEMBL6904204 | 0.83 | AHCY (0.34) | AHCY | |
| SCHEMBL6904243 | 0.80 | FGFR1 (0.46) | FGFR1SLC22A6HPRT1AHCYCYP3A4 | |
| SCHEMBL6903487 | 0.79 | FGFR1 (0.43) | FGFR1SLC22A6HPRT1AHCYCYP3A4 | |
| SCHEMBL6905047 | 0.79 | FGFR1 (0.45) | FGFR1SLC22A6HPRT1AHCYCYP3A4 | |
| SCHEMBL6316076 | 0.79 | FGFR1 (0.61) | FGFR1SLC22A6HPRT1AHCYCYP3A4 | |
| SCHEMBL6899073 | 0.79 | FDPS (0.51) | FGFR1SLC22A6HPRT1AHCYCYP3A4 | |
| SCHEMBL6903666 | 0.79 | FGFR1 (0.45) | FGFR1SLC22A6HPRT1AHCYCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014722-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | NSUN2, POLR2H, NSUN3 | FGFR1 2799/4885SLC22A6 3360/4885HPRT1 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.